Gennex Laboratories share news, announcements and annual reports
BSE: 531739Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 28 Oct 2026. Previous close ₹8.88.
28 Oct: open ₹8.80, high ₹9.21, low ₹8.80
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹221 Cr2,248th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 12.03
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 0.99
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 9.0%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 7.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.15
- Volume, BSEVolume. Shares traded on the last trading day. Volume in the glossary
- 2,86,354
Gennex Laboratories share news and announcements
553 announcements, routine notices left out, newest first. Page 2 of 12.
Jul 2025
8 Jul · Board meeting
Meeting on 8 Jul 2025: preferential issue of shares4 Jul · Board meeting
Meeting on 4 Jul 2025: preferential issue of shares
Jun 2025
4 Jun · Board meeting
Meeting on 4 Jun 2025: preferential issue of shares
May 2025
22 May · Approval Of Additional Products From Drugs Control Administration, Government Of Andhra Pradesh For Our Subsidiary Company, Deccan Remedies Limited
20 May · Board meeting
Meeting on 30 May 2025: audited results
Mar 2025
Feb 2025
3 Feb · Board meeting
Meeting on 14 Feb 2025: quarterly results
Nov 2024
14 Nov · Intimation Of Reconstitution Of Audit Committee, Stakeholders Relationship Committee And Nomination And Remuneration Committee Under Regulation 30 Of The SEBI (Listing Obligation And Disclosure Requirement) Regulations, 2015.
5 Nov · Board meeting
Meeting on 14 Nov 2024: quarterly results
Oct 2024
28 Oct · Grant Of Test License By Drugs Control Administration, Government Of Andhra Pradesh To Our Subsidiary Company, Deccan Remedies Limited
28 Oct · Approval Of Additional Products From Drug Control Administration, Government Of Andhra Pradesh For Our Subsidiary Company, Deccan Remedies Limited
Sep 2024
Aug 2024
28 Aug · Board meeting
Meeting on 6 Sep 2024: annual general meeting5 Aug · Board meeting
Meeting on 14 Aug 2024: quarterly results